Outcomes in 529 patients receiving HCT for secondary or de novo MDS (multivariate analysis)
| . | Relapse-free survival, 340 events . | Relapse, 128 events . | Nonrelapse mortality, 212 events . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Disease stage | <.001 | <.001 | .34 | |||
| RA/RARS | 1.0 | 1.0 | 1.0 | |||
| RAEB | 1.31 (0.9-1.8) | 2.78 (1.5-5.2) | 0.91 (0.6-1.4) | |||
| CMML | 1.31 (0.8-2.2) | 2.42 (0.9-6.4) | 1.03 (0.5-2.0) | |||
| RAEB-tAML | 2.15 (1.6-2.9) | 6.15 (3.5-11) | 1.25 (0.9-1.8) | |||
| Cytogenetic risk group | <.001 | <.001 | .07 | |||
| Good | 1.0 | 1.0 | 1.0 | |||
| Intermediate | 1.19 (0.9-1.6) | 2.00 (1.1-3.5) | 0.92 (0.6-1.4) | |||
| Poor | 2.01 (1.6-2.6) | 4.30 (2.7-6.8) | 1.37 (1.0-1.9) | |||
| Donor relation | .13 | .01 | .96 | |||
| Related | 1.0 | 1.0 | 1.0 | |||
| Unrelated | 0.83 (0.7-1.1) | 0.59 (0.4-0.9) | 0.99 (0.7-1.3) | |||
| Time from diagnosis to transplantation, mo | .52 | .92 | .12 | |||
| 0 to 6 | 1.0 | 1.0 | 1.0 | |||
| 7 to 12 | 1.11 (0.8-1.4) | 0.88 (0.6-1.4) | 1.34 (1.0-1.9) | |||
| 13 to 24 | 1.28 (0.9-1.8) | 0.93 (0.5-1.7) | 1.61 (1.1-2.4) | |||
| Longer than 24 | 1.00 (0.7-1.5) | 0.82 (0.4-1.7) | 1.18 (0.7-1.9) | |||
| Stem cell source | .36 | .31 | .55 | |||
| BM | 1.0 | 1.0 | 1.0 | |||
| PBSCs | 0.86 (0.6-1.2) | 0.76 (0.4-1.3) | 0.89 (0.6-1.3) | |||
| Conditioning regimen | .10 | .06 | .03 | |||
| Any TBI | 1.0 | 1.0 | 1.0 | |||
| BUCY | 0.66 (0.4-1.0) | 0.38 (0.2-0.8) | 0.79 (0.5-1.3) | |||
| t BUCY | 0.71 (0.5-1.0) | 1.08 (0.7-1.8) | 0.54 (0.4-0.8) | |||
| FLutBU | 1.20 (0.7-2.1) | 2.54 (1.1-6.0) | 0.76 (0.3-1.7) | |||
| FLuTBI(200) | 0.70 (0.4-1.3) | 0.69 (0.2-2.1) | 0.77 (0.3-1.7) | |||
| Year of transplantation | .31 | .47 | .05 | |||
| 2000 to 2006 | 1.0 | 1.0 | 1.0 | |||
| 1990 to 1999 | 1.19 (0.8-1.7) | 0.81 (0.5-1.4) | 1.57 (1.0-2.5) | |||
| Age at transplantation, y | .001 | .18 | .001 | |||
| Younger than 50 | 1.0 | 1.0 | 1.0 | |||
| 50 or older | 1.49 (1.2-1.9) | 1.31 (0.9-1.9) | 1.65 (1.2-2.2) | |||
| Etiology | .16 | .79 | .28 | |||
| De novo | 1.0 | 1.0 | 1.0 | |||
| Secondary | 1.19 (0.9-1.5) | 1.06 (0.7-1.6) | 1.18 (0.9-1.6) | |||
| . | Relapse-free survival, 340 events . | Relapse, 128 events . | Nonrelapse mortality, 212 events . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Disease stage | <.001 | <.001 | .34 | |||
| RA/RARS | 1.0 | 1.0 | 1.0 | |||
| RAEB | 1.31 (0.9-1.8) | 2.78 (1.5-5.2) | 0.91 (0.6-1.4) | |||
| CMML | 1.31 (0.8-2.2) | 2.42 (0.9-6.4) | 1.03 (0.5-2.0) | |||
| RAEB-tAML | 2.15 (1.6-2.9) | 6.15 (3.5-11) | 1.25 (0.9-1.8) | |||
| Cytogenetic risk group | <.001 | <.001 | .07 | |||
| Good | 1.0 | 1.0 | 1.0 | |||
| Intermediate | 1.19 (0.9-1.6) | 2.00 (1.1-3.5) | 0.92 (0.6-1.4) | |||
| Poor | 2.01 (1.6-2.6) | 4.30 (2.7-6.8) | 1.37 (1.0-1.9) | |||
| Donor relation | .13 | .01 | .96 | |||
| Related | 1.0 | 1.0 | 1.0 | |||
| Unrelated | 0.83 (0.7-1.1) | 0.59 (0.4-0.9) | 0.99 (0.7-1.3) | |||
| Time from diagnosis to transplantation, mo | .52 | .92 | .12 | |||
| 0 to 6 | 1.0 | 1.0 | 1.0 | |||
| 7 to 12 | 1.11 (0.8-1.4) | 0.88 (0.6-1.4) | 1.34 (1.0-1.9) | |||
| 13 to 24 | 1.28 (0.9-1.8) | 0.93 (0.5-1.7) | 1.61 (1.1-2.4) | |||
| Longer than 24 | 1.00 (0.7-1.5) | 0.82 (0.4-1.7) | 1.18 (0.7-1.9) | |||
| Stem cell source | .36 | .31 | .55 | |||
| BM | 1.0 | 1.0 | 1.0 | |||
| PBSCs | 0.86 (0.6-1.2) | 0.76 (0.4-1.3) | 0.89 (0.6-1.3) | |||
| Conditioning regimen | .10 | .06 | .03 | |||
| Any TBI | 1.0 | 1.0 | 1.0 | |||
| BUCY | 0.66 (0.4-1.0) | 0.38 (0.2-0.8) | 0.79 (0.5-1.3) | |||
| t BUCY | 0.71 (0.5-1.0) | 1.08 (0.7-1.8) | 0.54 (0.4-0.8) | |||
| FLutBU | 1.20 (0.7-2.1) | 2.54 (1.1-6.0) | 0.76 (0.3-1.7) | |||
| FLuTBI(200) | 0.70 (0.4-1.3) | 0.69 (0.2-2.1) | 0.77 (0.3-1.7) | |||
| Year of transplantation | .31 | .47 | .05 | |||
| 2000 to 2006 | 1.0 | 1.0 | 1.0 | |||
| 1990 to 1999 | 1.19 (0.8-1.7) | 0.81 (0.5-1.4) | 1.57 (1.0-2.5) | |||
| Age at transplantation, y | .001 | .18 | .001 | |||
| Younger than 50 | 1.0 | 1.0 | 1.0 | |||
| 50 or older | 1.49 (1.2-1.9) | 1.31 (0.9-1.9) | 1.65 (1.2-2.2) | |||
| Etiology | .16 | .79 | .28 | |||
| De novo | 1.0 | 1.0 | 1.0 | |||
| Secondary | 1.19 (0.9-1.5) | 1.06 (0.7-1.6) | 1.18 (0.9-1.6) | |||
Disease categories and conditioning regimens as per legends to Tables 1 and 3. RA/RARS also comprises RCMD, MDS-U, and 5q- (<5% myeloblasts). RAEB comprises RAEB-1 and -2 (by WHO); CMML comprises CMML-1 and -2 (by WHO).
tAML indicates AML with multilineage dysplasia arising from MDS; mo, months; BM, bone marrow; and PBPCs, peripheral blood progenitor cells.
*Classified by IPSS criteria.